Brainsway Ltd. current report, Q2 FY2021

Business Context and Reporting Period

This Form 6-K filing by Brainsway Ltd. covers the month of June 2021, specifically reporting on the completion of an exchange offer for employee stock options. The filing was signed on June 3, 2021.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the mechanics of a stock option exchange program.

Material Changes

The primary material change reported is the successful completion of an Exchange Offer to replace eligible employee stock options with new options featuring modified terms:

  • Participation Rate: The Company accepted for cancellation Eligible Options to purchase an aggregate of 1,371,500 Ordinary Shares, representing approximately 93.06% of the total Ordinary Shares underlying the Eligible Options.
  • New Grant: On June 2, 2021, the Company granted New Options to purchase 1,371,500 Ordinary Shares.
  • Exercise Price Adjustment: The exercise price for the New Options is set at US$4.675 per Ordinary Share. This price is based on half of the closing price of the Company's American Depositary Share (ADS) on January 25, 2021.
  • Terms: Each New Option retains the same expiration date, vesting schedule, and other terms as the Eligible Option exchanged, except for the exercise price.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the details of the option exchange.

Investor Verification Checklist

  • Verify the impact of the new exercise price (US$4.675) on the intrinsic value of the options compared to the current market price.
  • Confirm the total number of shares underlying the remaining 6.94% of Eligible Options that were not exchanged.
  • Review the Company's 2014 Share Incentive Plan and the Amended and Restated 2019 Share Incentive Plan for full details on vesting schedules and expiration dates.
  • Check subsequent filings for any dilution effects resulting from the grant of 1,371,500 New Options.